APO Research
Talk to an analyst

APO RESEARCH · REPORT

Idiopathic Pulmonary Fibrosis Disease Treatment

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Idiopathic Pulmonary Fibrosis Disease Treatment Market Outlook and Growth Opportunities 2026

2 January 2026199 pages

Choose your research edition.

Industry ResearchIdiopathic Pulmonary Fibrosis Disease Treatment Industry Research Report 2026118 pages · $2,950 USDIndustry Growth & TrendsGlobal Idiopathic Pulmonary Fibrosis Disease Treatment Industry Growth and Trends Forecast to 2032101 pages · $3,450 USDMarket StructureGlobal Idiopathic Pulmonary Fibrosis Disease Treatment Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Idiopathic Pulmonary Fibrosis Disease Treatment Market Outlook and Growth Opportunities 2026199 pages · $4,250 USDMarket Analysis & ForecastGlobal Idiopathic Pulmonary Fibrosis Disease Treatment Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global Idiopathic Pulmonary Fibrosis Disease Treatment market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Idiopathic Pulmonary Fibrosis Disease Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Idiopathic Pulmonary Fibrosis Disease Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Idiopathic Pulmonary Fibrosis Disease Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Idiopathic Pulmonary Fibrosis Disease Treatment market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Idiopathic Pulmonary Fibrosis Disease Treatment market include Blade Therapeutics, Bristol Myers Squibb, InterMune, Inc., Vicore Pharma, ArkBio, Boehringer Ingelheim, Regend Therapeutics (Cayman) Ltd., Merck and Co., Inc. and SHIONOGI & CO., Ltd., among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Idiopathic Pulmonary Fibrosis Disease Treatment market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Idiopathic Pulmonary Fibrosis Disease Treatment and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Idiopathic Pulmonary Fibrosis Disease Treatment revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Idiopathic Pulmonary Fibrosis Disease Treatment market.

Idiopathic Pulmonary Fibrosis Disease Treatment Segment by Company

Blade Therapeutics

Bristol Myers Squibb

InterMune, Inc.

Vicore Pharma

ArkBio

Boehringer Ingelheim

Regend Therapeutics (Cayman) Ltd.

Merck and Co., Inc.

SHIONOGI & CO., Ltd.

Insilico Medicine

Indaco

Zelgen

Heilongjiang Zbd Pharmaceutical

Idiopathic Pulmonary Fibrosis Disease Treatment Segment by Type

Pirfenidone

Nintedanib

Other

Idiopathic Pulmonary Fibrosis Disease Treatment Segment by Application

Hospital

Graduate School

Others

Idiopathic Pulmonary Fibrosis Disease Treatment Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Idiopathic Pulmonary Fibrosis Disease Treatment status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Idiopathic Pulmonary Fibrosis Disease Treatment key companies, revenue, market share, and recent developments.

3. To split the Idiopathic Pulmonary Fibrosis Disease Treatment breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Idiopathic Pulmonary Fibrosis Disease Treatment market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Idiopathic Pulmonary Fibrosis Disease Treatment significant trends, drivers, influence factors in global and regions.

6. To analyze Idiopathic Pulmonary Fibrosis Disease Treatment competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Idiopathic Pulmonary Fibrosis Disease Treatment market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Idiopathic Pulmonary Fibrosis Disease Treatment and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Idiopathic Pulmonary Fibrosis Disease Treatment.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Idiopathic Pulmonary Fibrosis Disease Treatment industry.

Chapter 3: Detailed analysis of Idiopathic Pulmonary Fibrosis Disease Treatment company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Idiopathic Pulmonary Fibrosis Disease Treatment in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Idiopathic Pulmonary Fibrosis Disease Treatment in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Idiopathic Pulmonary Fibrosis Disease Treatment Industry Trends Table 2. Idiopathic Pulmonary Fibrosis Disease Treatment Industry Drivers Table 3. Idiopathic Pulmonary Fibrosis Disease Treatment Industry Opportunities and Challenges Table 4. Idiopathic Pulmonary Fibrosis Disease Treatment Industry Restraints Table 5. Global Idiopathic Pulmonary Fibrosis Disease Treatment Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Idiopathic Pulmonary Fibrosis Disease Treatment Revenue Share by Company (2021-2026) Table 7. Global Idiopathic Pulmonary Fibrosis Disease Treatment Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Idiopathic Pulmonary Fibrosis Disease Treatment Key Company Manufacturing Base & Headquarters Table 9. Global Idiopathic Pulmonary Fibrosis Disease Treatment Company, Product Type & Application Table 10. Global Idiopathic Pulmonary Fibrosis Disease Treatment Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Idiopathic Pulmonary Fibrosis Disease Treatment by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Pirfenidone Table 15. Significant Companies of Nintedanib Table 16. Significant Companies of Other Table 17. Global Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 18. Global Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value by Type (2021-2026) & (US$ Million) Table 19. Global Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value by Type (2027-2032) & (US$ Million) Table 20. Global Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value Share by Type (2021-2026) Table 21. Global Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value Share by Type (2027-2032) Table 22. Significant Companies of Hospital Table 23. Significant Companies of Graduate School Table 24. Significant Companies of Others Table 25. Global Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value by Application (2021-2026) & (US$ Million) Table 27. Global Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value by Application (2027-2032) & (US$ Million) Table 28. Global Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value Share by Application (2021-2026) Table 29. Global Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value Share by Application (2027-2032) Table 30. Global Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value by Region (2021-2026) & (US$ Million) Table 32. Global Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value Share by Region (2021-2026) Table 33. Global Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value by Region (2027-2032) & (US$ Million) Table 34. Global Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value Share by Region (2027-2032) Table 35. Global Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 36. Global Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value by Country (2021-2026) & (US$ Million) Table 37. Global Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value Market Share by Country (2021-2026) Table 38. Global Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value by Country (2027-2032) & (US$ Million) Table 39. Global Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value Market Share by Country (2027-2032) Table 40. Blade Therapeutics Company Information Table 41. Blade Therapeutics Business Overview Table 42. Blade Therapeutics Idiopathic Pulmonary Fibrosis Disease Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 43. Blade Therapeutics Idiopathic Pulmonary Fibrosis Disease Treatment Product Portfolio Table 44. Blade Therapeutics Recent Development Table 45. Bristol Myers Squibb Company Information Table 46. Bristol Myers Squibb Business Overview Table 47. Bristol Myers Squibb Idiopathic Pulmonary Fibrosis Disease Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 48. Bristol Myers Squibb Idiopathic Pulmonary Fibrosis Disease Treatment Product Portfolio Table 49. Bristol Myers Squibb Recent Development Table 50. InterMune, Inc. Company Information Table 51. InterMune, Inc. Business Overview Table 52. InterMune, Inc. Idiopathic Pulmonary Fibrosis Disease Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 53. InterMune, Inc. Idiopathic Pulmonary Fibrosis Disease Treatment Product Portfolio Table 54. InterMune, Inc. Recent Development Table 55. Vicore Pharma Company Information Table 56. Vicore Pharma Business Overview Table 57. Vicore Pharma Idiopathic Pulmonary Fibrosis Disease Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 58. Vicore Pharma Idiopathic Pulmonary Fibrosis Disease Treatment Product Portfolio Table 59. Vicore Pharma Recent Development Table 60. ArkBio Company Information Table 61. ArkBio Business Overview Table 62. ArkBio Idiopathic Pulmonary Fibrosis Disease Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 63. ArkBio Idiopathic Pulmonary Fibrosis Disease Treatment Product Portfolio Table 64. ArkBio Recent Development Table 65. Boehringer Ingelheim Company Information Table 66. Boehringer Ingelheim Business Overview Table 67. Boehringer Ingelheim Idiopathic Pulmonary Fibrosis Disease Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 68. Boehringer Ingelheim Idiopathic Pulmonary Fibrosis Disease Treatment Product Portfolio Table 69. Boehringer Ingelheim Recent Development Table 70. Regend Therapeutics (Cayman) Ltd. Company Information Table 71. Regend Therapeutics (Cayman) Ltd. Business Overview Table 72. Regend Therapeutics (Cayman) Ltd. Idiopathic Pulmonary Fibrosis Disease Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. Regend Therapeutics (Cayman) Ltd. Idiopathic Pulmonary Fibrosis Disease Treatment Product Portfolio Table 74. Regend Therapeutics (Cayman) Ltd. Recent Development Table 75. Merck and Co., Inc. Company Information Table 76. Merck and Co., Inc. Business Overview Table 77. Merck and Co., Inc. Idiopathic Pulmonary Fibrosis Disease Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. Merck and Co., Inc. Idiopathic Pulmonary Fibrosis Disease Treatment Product Portfolio Table 79. Merck and Co., Inc. Recent Development Table 80. SHIONOGI & CO., Ltd. Company Information Table 81. SHIONOGI & CO., Ltd. Business Overview Table 82. SHIONOGI & CO., Ltd. Idiopathic Pulmonary Fibrosis Disease Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 83. SHIONOGI & CO., Ltd. Idiopathic Pulmonary Fibrosis Disease Treatment Product Portfolio Table 84. SHIONOGI & CO., Ltd. Recent Development Table 85. Insilico Medicine Company Information Table 86. Insilico Medicine Business Overview Table 87. Insilico Medicine Idiopathic Pulmonary Fibrosis Disease Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 88. Insilico Medicine Idiopathic Pulmonary Fibrosis Disease Treatment Product Portfolio Table 89. Insilico Medicine Recent Development Table 90. Indaco Company Information Table 91. Indaco Business Overview Table 92. Indaco Idiopathic Pulmonary Fibrosis Disease Treatment Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 93. Indaco Idiopathic Pulmonary Fibrosis Disease Treatment Product Portfolio Table 94. Indaco Recent Development Table 95. Zelgen Company Information Table 96. Zelgen Business Overview Table 97. Zelgen Idiopathic Pulmonary Fibrosis Disease Treatment Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 98. Zelgen Idiopathic Pulmonary Fibrosis Disease Treatment Product Portfolio Table 99. Zelgen Recent Development Table 100. Heilongjiang Zbd Pharmaceutical Company Information Table 101. Heilongjiang Zbd Pharmaceutical Business Overview Table 102. Heilongjiang Zbd Pharmaceutical Idiopathic Pulmonary Fibrosis Disease Treatment Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 103. Heilongjiang Zbd Pharmaceutical Idiopathic Pulmonary Fibrosis Disease Treatment Product Portfolio Table 104. Heilongjiang Zbd Pharmaceutical Recent Development Table 105. Research Programs/Design for This Report Table 106. Authors List of This Report Table 107. Secondary Sources Table 108. Primary Sources List of Figures Figure 1. Idiopathic Pulmonary Fibrosis Disease Treatment Product Image Figure 2. Global Idiopathic Pulmonary Fibrosis Disease Treatment Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Idiopathic Pulmonary Fibrosis Disease Treatment Market Size (2021-2032) & (US$ Million) Figure 4. Global Idiopathic Pulmonary Fibrosis Disease Treatment Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Pirfenidone Image Figure 8. Nintedanib Image Figure 9. Other Image Figure 10. Global Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 11. Global Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value Share 2021 VS 2025 VS 2032 Figure 12. Global Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value Share by Type (2021-2032) Figure 13. Hospital Image Figure 14. Graduate School Image Figure 15. Others Image Figure 16. Global Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value Share by Application (2021-2032) Figure 19. Global Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 20. Global Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 21. North America Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value (2021-2032) & (US$ Million) Figure 22. North America Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 23. Europe Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value (2021-2032) & (US$ Million) Figure 24. Europe Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 25. Asia-Pacific Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value (2021-2032) & (US$ Million) Figure 26. Asia-Pacific Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 27. South America Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value (2021-2032) & (US$ Million) Figure 28. South America Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 29. Middle East & Africa Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value (2021-2032) & (US$ Million) Figure 30. Middle East & Africa Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 31. USA Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 32. USA Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 33. USA Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 34. Canada Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 35. Canada Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 36. Canada Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 37. Mexico Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 38. Mexico Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 39. Mexico Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 40. Germany Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. Germany Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. Germany Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. France Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. France Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. France Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. U.K. Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. U.K. Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. U.K. Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Italy Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Italy Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Italy Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Spain Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Spain Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Spain Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. Russia Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. Russia Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. Russia Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Netherlands Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Netherlands Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Netherlands Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Nordic Countries Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Nordic Countries Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Nordic Countries Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. China Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. China Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. China Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Japan Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Japan Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Japan Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. South Korea Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. South Korea Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. South Korea Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. India Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. India Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. India Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Australia Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Australia Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Australia Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Southeast Asia Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Southeast Asia Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Southeast Asia Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. Brazil Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. Brazil Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. Brazil Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Argentina Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Argentina Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Argentina Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Chile Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Chile Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Chile Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Colombia Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Colombia Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Colombia Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Peru Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Peru Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Peru Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Saudi Arabia Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Saudi Arabia Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Saudi Arabia Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Israel Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Israel Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Israel Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. UAE Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. UAE Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. UAE Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Turkey Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Turkey Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Turkey Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Iran Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Iran Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Iran Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Egypt Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Egypt Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Egypt Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Years Considered Figure 116. Research Process Figure 117. Key Executives Interviewed

Scope & coverage.

Types
  • Pirfenidone
  • Nintedanib
  • Other
Applications
  • Hospital
  • Graduate School
  • Others
Companies covered
  • Blade Therapeutics
  • Bristol Myers Squibb
  • InterMune, Inc.
  • Vicore Pharma
  • ArkBio
  • Boehringer Ingelheim
  • Regend Therapeutics (Cayman) Ltd.
  • Merck and Co., Inc.
  • SHIONOGI & CO., Ltd.
  • Insilico Medicine
  • Indaco
  • Zelgen
  • Heilongjiang Zbd Pharmaceutical

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Idiopathic Pulmonary Fibrosis Disease Treatment Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Idiopathic Pulmonary Fibrosis Disease Treatment Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Idiopathic Pulmonary Fibrosis Disease Treatment Market Dynamics
  1. 2.1 Idiopathic Pulmonary Fibrosis Disease Treatment Industry Trends
  2. 2.2 Idiopathic Pulmonary Fibrosis Disease Treatment Industry Drivers
  3. 2.3 Idiopathic Pulmonary Fibrosis Disease Treatment Industry Opportunities and Challenges
  4. 2.4 Idiopathic Pulmonary Fibrosis Disease Treatment Industry Restraints
3 Idiopathic Pulmonary Fibrosis Disease Treatment Market by Company
  1. 3.1 Global Idiopathic Pulmonary Fibrosis Disease Treatment Company Revenue Ranking in 2025
  2. 3.2 Global Idiopathic Pulmonary Fibrosis Disease Treatment Revenue by Company (2021-2026)
  3. 3.3 Global Idiopathic Pulmonary Fibrosis Disease Treatment Company Ranking (2024-2026)
  4. 3.4 Global Idiopathic Pulmonary Fibrosis Disease Treatment Company Manufacturing Base and Headquarters
  5. 3.5 Global Idiopathic Pulmonary Fibrosis Disease Treatment Company Product Type and Application
  6. 3.6 Global Idiopathic Pulmonary Fibrosis Disease Treatment Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Idiopathic Pulmonary Fibrosis Disease Treatment Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Idiopathic Pulmonary Fibrosis Disease Treatment Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Idiopathic Pulmonary Fibrosis Disease Treatment Market by Type
  1. 4.1 Idiopathic Pulmonary Fibrosis Disease Treatment Type Introduction
  2. 4.1.1 Pirfenidone
  3. 4.1.2 Nintedanib
  4. 4.1.3 Other
  5. 4.2 Global Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value by Type
  6. 4.2.1 Global Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value by Type (2021-2032)
  8. 4.2.3 Global Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value Share by Type (2021-2032)
5 Idiopathic Pulmonary Fibrosis Disease Treatment Market by Application
  1. 5.1 Idiopathic Pulmonary Fibrosis Disease Treatment Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Graduate School
  4. 5.1.3 Others
  5. 5.2 Global Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value by Application
  6. 5.2.1 Global Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value by Application (2021-2032)
  8. 5.2.3 Global Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value Share by Application (2021-2032)
6 Idiopathic Pulmonary Fibrosis Disease Treatment Regional Value Analysis
  1. 6.1 Global Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value by Region (2021-2032)
  3. 6.2.1 Global Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value by Region: 2021-2026
  4. 6.2.2 Global Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value (2021-2032)
  7. 6.3.2 North America Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value (2021-2032)
  10. 6.4.2 Europe Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value (2021-2032)
  16. 6.6.2 South America Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value Share by Country, 2025 VS 2032
7 Idiopathic Pulmonary Fibrosis Disease Treatment Country-level Value Analysis
  1. 7.1 Global Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value by Country (2021-2032)
  3. 7.2.1 Global Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value by Country (2021-2026)
  4. 7.2.2 Global Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Idiopathic Pulmonary Fibrosis Disease Treatment Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Blade Therapeutics
  2. 8.1.1 Blade Therapeutics Company Information
  3. 8.1.2 Blade Therapeutics Business Overview
  4. 8.1.3 Blade Therapeutics Idiopathic Pulmonary Fibrosis Disease Treatment Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Blade Therapeutics Idiopathic Pulmonary Fibrosis Disease Treatment Product Portfolio
  6. 8.1.5 Blade Therapeutics Recent Developments
  7. 8.2 Bristol Myers Squibb
  8. 8.2.1 Bristol Myers Squibb Company Information
  9. 8.2.2 Bristol Myers Squibb Business Overview
  10. 8.2.3 Bristol Myers Squibb Idiopathic Pulmonary Fibrosis Disease Treatment Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Bristol Myers Squibb Idiopathic Pulmonary Fibrosis Disease Treatment Product Portfolio
  12. 8.2.5 Bristol Myers Squibb Recent Developments
  13. 8.3 InterMune, Inc.
  14. 8.3.1 InterMune, Inc. Company Information
  15. 8.3.2 InterMune, Inc. Business Overview
  16. 8.3.3 InterMune, Inc. Idiopathic Pulmonary Fibrosis Disease Treatment Revenue and Gross Margin (2021-2026)
  17. 8.3.4 InterMune, Inc. Idiopathic Pulmonary Fibrosis Disease Treatment Product Portfolio
  18. 8.3.5 InterMune, Inc. Recent Developments
  19. 8.4 Vicore Pharma
  20. 8.4.1 Vicore Pharma Company Information
  21. 8.4.2 Vicore Pharma Business Overview
  22. 8.4.3 Vicore Pharma Idiopathic Pulmonary Fibrosis Disease Treatment Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Vicore Pharma Idiopathic Pulmonary Fibrosis Disease Treatment Product Portfolio
  24. 8.4.5 Vicore Pharma Recent Developments
  25. 8.5 ArkBio
  26. 8.5.1 ArkBio Company Information
  27. 8.5.2 ArkBio Business Overview
  28. 8.5.3 ArkBio Idiopathic Pulmonary Fibrosis Disease Treatment Revenue and Gross Margin (2021-2026)
  29. 8.5.4 ArkBio Idiopathic Pulmonary Fibrosis Disease Treatment Product Portfolio
  30. 8.5.5 ArkBio Recent Developments
  31. 8.6 Boehringer Ingelheim
  32. 8.6.1 Boehringer Ingelheim Company Information
  33. 8.6.2 Boehringer Ingelheim Business Overview
  34. 8.6.3 Boehringer Ingelheim Idiopathic Pulmonary Fibrosis Disease Treatment Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Boehringer Ingelheim Idiopathic Pulmonary Fibrosis Disease Treatment Product Portfolio
  36. 8.6.5 Boehringer Ingelheim Recent Developments
  37. 8.7 Regend Therapeutics (Cayman) Ltd.
  38. 8.7.1 Regend Therapeutics (Cayman) Ltd. Company Information
  39. 8.7.2 Regend Therapeutics (Cayman) Ltd. Business Overview
  40. 8.7.3 Regend Therapeutics (Cayman) Ltd. Idiopathic Pulmonary Fibrosis Disease Treatment Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Regend Therapeutics (Cayman) Ltd. Idiopathic Pulmonary Fibrosis Disease Treatment Product Portfolio
  42. 8.7.5 Regend Therapeutics (Cayman) Ltd. Recent Developments
  43. 8.8 Merck and Co., Inc.
  44. 8.8.1 Merck and Co., Inc. Company Information
  45. 8.8.2 Merck and Co., Inc. Business Overview
  46. 8.8.3 Merck and Co., Inc. Idiopathic Pulmonary Fibrosis Disease Treatment Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Merck and Co., Inc. Idiopathic Pulmonary Fibrosis Disease Treatment Product Portfolio
  48. 8.8.5 Merck and Co., Inc. Recent Developments
  49. 8.9 SHIONOGI & CO., Ltd.
  50. 8.9.1 SHIONOGI & CO., Ltd. Company Information
  51. 8.9.2 SHIONOGI & CO., Ltd. Business Overview
  52. 8.9.3 SHIONOGI & CO., Ltd. Idiopathic Pulmonary Fibrosis Disease Treatment Revenue and Gross Margin (2021-2026)
  53. 8.9.4 SHIONOGI & CO., Ltd. Idiopathic Pulmonary Fibrosis Disease Treatment Product Portfolio
  54. 8.9.5 SHIONOGI & CO., Ltd. Recent Developments
  55. 8.10 Insilico Medicine
  56. 8.10.1 Insilico Medicine Company Information
  57. 8.10.2 Insilico Medicine Business Overview
  58. 8.10.3 Insilico Medicine Idiopathic Pulmonary Fibrosis Disease Treatment Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Insilico Medicine Idiopathic Pulmonary Fibrosis Disease Treatment Product Portfolio
  60. 8.10.5 Insilico Medicine Recent Developments
  61. 8.11 Indaco
  62. 8.11.1 Indaco Company Information
  63. 8.11.2 Indaco Business Overview
  64. 8.11.3 Indaco Idiopathic Pulmonary Fibrosis Disease Treatment Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Indaco Idiopathic Pulmonary Fibrosis Disease Treatment Product Portfolio
  66. 8.11.5 Indaco Recent Developments
  67. 8.12 Zelgen
  68. 8.12.1 Zelgen Company Information
  69. 8.12.2 Zelgen Business Overview
  70. 8.12.3 Zelgen Idiopathic Pulmonary Fibrosis Disease Treatment Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Zelgen Idiopathic Pulmonary Fibrosis Disease Treatment Product Portfolio
  72. 8.12.5 Zelgen Recent Developments
  73. 8.13 Heilongjiang Zbd Pharmaceutical
  74. 8.13.1 Heilongjiang Zbd Pharmaceutical Company Information
  75. 8.13.2 Heilongjiang Zbd Pharmaceutical Business Overview
  76. 8.13.3 Heilongjiang Zbd Pharmaceutical Idiopathic Pulmonary Fibrosis Disease Treatment Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Heilongjiang Zbd Pharmaceutical Idiopathic Pulmonary Fibrosis Disease Treatment Product Portfolio
  78. 8.13.5 Heilongjiang Zbd Pharmaceutical Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst